TMC Life Sciences Bhd (XKLS:0101) EBIT: RM29.7 Mil (TTM As of Mar. 2026)


XKLS:0101 TMC Life Sciences Bhd XKLS:0101
62 GF Score
Price RM0.45
GF Value RM0.62
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is TMC Life Sciences Bhd EBIT?

TMC Life Sciences Bhd XKLS:0101 62 EBIT is RM29.7 Mil as of Mar. 2026. GuruFocus rates XKLS:0101 with a GF Score™ of 62/100 and a GF Value™ of RM0.62 (Modestly Undervalued). The stock has 3 warning signs investors should review.

TMC Life Sciences Bhd's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was RM4.6 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was RM29.7 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. TMC Life Sciences Bhd's annualized ROC % for the quarter that ended in Mar. 2026 was 1.02%. TMC Life Sciences Bhd's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 2.47%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. TMC Life Sciences Bhd's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 3.62%.

TMC Life Sciences Bhd  (XKLS:0101) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

TMC Life Sciences Bhd's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=15.308 * ( 1 - 36.05% )/( (964.837 + 962.124)/ 2 )
=9.789466/963.4805
=1.02 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1119.148 - 60.557 - ( 112.896 - max(0, 107.828 - 201.582+112.896))
=964.837

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1110.002 - 59.625 - ( 118.116 - max(0, 107.114 - 195.367+118.116))
=962.124

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

TMC Life Sciences Bhd's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=18.22/( ( (716.29 + max(27.602, 0)) + (715.103 + max(17.073, 0)) )/ 2 )
=18.22/( ( 743.892 + 732.176 )/ 2 )
=18.22/738.034
=2.47 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(64.053 + 17.634 + 6.999) - (60.557 + 0 + 0.527)
=27.602

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(57.869 + 18.638 + 0.744) - (59.625 + 0 + 0.553)
=17.073

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

TMC Life Sciences Bhd's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=29.741/821.884
=3.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TMC Life Sciences Bhd EBIT Related Terms

TMC Life Sciences Bhd EBIT Historical Data

* Premium members only.

The historical data trend for TMC Life Sciences Bhd's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TMC Life Sciences Bhd EBIT Chart

TMC Life Sciences Bhd Annual Data
Trend May15 May16 Aug17 Aug18 Aug19 Jun21 Jun22 Jun23 Jun24 Jun25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.11 34.28 50.30 62.88 16.41

TMC Life Sciences Bhd Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.34 5.29 8.62 11.28 4.56

XKLS:0101 vs HCA, THC, DVA: EBIT Comparison

For the Medical Care Facilities subindustry, TMC Life Sciences Bhd's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TMC Life Sciences Bhd EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, TMC Life Sciences Bhd's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where TMC Life Sciences Bhd's EV-to-EBIT falls into.


XKLS:0101
62GF Score
TMC Life Sciences Bhd XKLS:0101
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TMC Life Sciences Bhd EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was RM29.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of RM29.7 Mil mean?
TMC Life Sciences Bhd (XKLS:0101) has a EBIT of RM29.7 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on TMC Life Sciences Bhd.
Is TMC Life Sciences Bhd's EBIT too high?
TMC Life Sciences Bhd's current EBIT is RM29.7 Mil. Overall, TMC Life Sciences Bhd has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TMC Life Sciences Bhd's EBIT compare to HCA and THC?
TMC Life Sciences Bhd's EBIT of RM29.7 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on TMC Life Sciences Bhd. TMC Life Sciences Bhd's current EBIT is RM29.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TMC Life Sciences Bhd stock overvalued right now?
Based on GuruFocus' analysis, TMC Life Sciences Bhd (XKLS:0101) is currently considered Modestly Undervalued. The stock's GF Value™ is RM0.62, compared to a current price of RM0.45 — trading 27.4% below its estimated fair value. The current EBIT is RM29.7 Mil. TMC Life Sciences Bhd's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For TMC Life Sciences Bhd (XKLS:0101), the current EBIT is RM29.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TMC Life Sciences Bhd (XKLS:0101) Overvalued in 2026?

Based on GuruFocus' analysis, TMC Life Sciences Bhd stock appears to be undervalued. The current stock price of RM0.45 is trading 27.4% below its estimated GF Value™ of RM0.62. GuruFocus considers TMC Life Sciences Bhd to be Modestly Undervalued.

Key valuation signals for XKLS:0101:

  • EBIT: RM29.7 Mil
  • GF Value™: RM0.62 vs. price of RM0.45 (27.4% below fair value)
  • GF Score™: 62/100 with 3 warning signs

No single metric tells the full story. See the XKLS:0101 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TMC Life Sciences Bhd Business Description

Address No. 11, PJU 5, Jalan Teknologi, Level 11, Taman Sains, Kota Damansara, Petaling Jaya, SGR, MYS, 47810
TMC Life Sciences Bhd is an investment holding company operating a multi-disciplinary tertiary care center and fertility center in Malaysia. It operates Tropicana Medical Centre, Kota Damansara (TMCKD), a medical center located in Petaling Jaya. Its TMCKD provides healthcare services in various medical/surgical specialties and subspecialties, including anesthesiology, cancer, cardiology, colorectal, dermatology, ENT, fertility, gastroenterology, as well as offers internal medicines and respiratory medicines. Its fertility center provides a range of fertility treatments for couples. The company also operates a women's clinic; provides fertility consultancy, laboratory, and embryology services; and offers pharmacy services and products.
62GF Score

Get the complete analysis for XKLS:0101

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

RM0.45
Price
RM0.62
GF Value